Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025PharmaceuticalsOpen Access

Qifu Decoction Alleviates Lipopolysaccharide-Induced Myocardial Dysfunction by Inhibiting TLR4/NF-κB/NLRP3 Inflammatory Pathway and Activating PPARα/CPT Pathway

View Full Paper
Ask AI
Bookmark
Share

Authors

LZLingxin ZhuoMMMingxuan MaJZJiayi Zhang

Discussion

Loading...

Member takes

Overview

Experimental analysis shows Qifu decoction reduces myocardial injury in SIC models, suggesting its potential for therapeutic use.

Key Points

  • Qifu decoction significantly improved cardiac function and reduced myocardial injury in sepsis-induced cardiomyopathy.
  • Serum levels of LDH, CK-MB, IL-1β, and TNF-α decreased by 28.7%, 32.3%, 38.6%, and 36.7%, respectively, after treatment.
  • Analysis utilized electrocardiography, histopathology, and metabolomic approaches to study Qifu decoction's effects.
  • The findings support the potential of Qifu decoction as a therapeutic agent for sepsis-induced cardiomyopathy.

Cite This Study

Zhuo et al. (2025) studied this question.

synapsesocial.com/papers/68c2409bb210217d6479b5a2https://doi.org/10.3390/ph18081109
View Full Paper
Ask AI
Bookmark
Share